Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 19/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4877656 | 0.91 | AOC3 (0.52) | AOC3CLK1 | |
| SCHEMBL27634159 | 0.86 | AOC3 (0.48) | AOC3MAOB | |
| SCHEMBL14019553 | 0.86 | AOC3 (0.52) | AOC3 | |
| SCHEMBL3936616 | 0.85 | AOC3 (0.49) | AOC3CLK1 | |
| SCHEMBL3936170 | 0.85 | AOC3 (0.49) | AOC3CLK1 | |
| SCHEMBL4874294 | 0.85 | AOC3 (0.47) | AOC3CLK1MAOB | |
| Hydrochloric Acid SCHEMBL4871250 | 0.85 | AOC3 (0.52) | AOC3 | |
| SCHEMBL4875662 | 0.83 | AOC3 (0.76) | AOC3 | |
| SCHEMBL27654557 | 0.82 | AOC3 (0.54) | AOC3CLK1MAOB | |
| SCHEMBL3934271 | 0.81 | AOC3 (0.60) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608365-B1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | R TECH UENO LTD (JP) | 2013-10-02 | — | — | EP | disclosed |
| US-7442715-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2008-10-28 | — | — | US | disclosed |
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | SUCAMPO AG (CH) | 2008-05-22 | — | — | US | disclosed |
| US-20060276521-A1 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-12-07 | — | — | US | disclosed |
| US-7125901-B2 | Thiazole derivatives | ASTELLAS PHARMA INC. (JP) | 2006-10-24 | — | — | US | disclosed |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | SUCAMPO AG (CH) | 2006-10-12 | — | — | US | disclosed |
| US-20060128770-A1 | Thiazole derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1587800-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | Astellas Pharma Inc. (JP) | 2005-10-26 | — | — | EP | disclosed |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-12-23 | — | — | US | disclosed |
| WO-2004067521-A1 | THIAZOLE DERIVATIVES AND THEIR USE AS VAP-1 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119462-A1 | METHOD FOR TREATING VASCULAR HYPERPERMEABLE DISEASE | VCAM1, ICAM1, VAPB | AOC3 202/4885CLK1 1674/4885MAOB 923/4885 |
| US-20060276521-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885CLK1 4018/4885MAOB 4191/4885 |
| US-20060229346-A1 | Method for treating vascular hyperpermeable disease | VCAM1, VAPB, ICAM1 | AOC3 85/4885CLK1 2525/4885MAOB 1422/4885 |
| US-20060128770-A1 | Thiazole derivatives | VCAM1, ICAM1, TXNL1 | AOC3 782/4885CLK1 4018/4885MAOB 4191/4885 |
| US-20040259923-A1 | Compound useful as cellular adhesion protein and as antiedemic agent | VCAM1, ICAM1, VAPB | AOC3 590/4885CLK1 3727/4885MAOB 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.